SequelSEC

Zura Bio Ltd ZURA

Biological Products, (No Diagnostic Substances) · CIK 0001855644 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-09-30
Operating income
-$102.00M
Fiscal year ended 2026-09-30
Free cash flow
-$64.94M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$58.99MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.62Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity0.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio9.05x77th

Zura Bio Ltd (ZURA) reported net income of -$93.53M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Zura Bio Ltd’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Zura Bio Ltd income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$102.00M
Net income-$93.53M
Research & development$65.90M
Weighted-average diluted sharesUnavailable
Pretax income-$94.83M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$36.10M
Selling & marketingUnavailable

Balance

Zura Bio Ltd balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$187.65M
Total assets$194.63M
Current assets$191.59M
Total liabilities$16.97M
Current liabilities$16.97M
Total equity incl. NCI$177.66M
Temporary (mezzanine) equity$0
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$758.00K

Cash flow

Zura Bio Ltd cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow-$64.83M
Capital expenditures$112.98K
Investing cash flow-$112.98K
Financing cash flow-$2.03M
Net change in cashUnavailable
Stock-based compensation$12.34M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$49.02K

Derived

Zura Bio Ltd derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow-$64.94M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio11.29x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZURA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-27View SEC filing
10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.